Science Seminar on benefits of biomedical research for patients
27 March 2006 - 27 March 2006
The seminar will explore how best to create an environment in Europe in which collaborative research can flourish.
The meeting will be chaired by Giles Chichester MEP, Chairman of the European Parliament’s Industry Committee and speakers will include the European Commissioner for Research, Janez Potočnik, Tachi Yamada, the Chairman of R&D at GlaxoSmithKline and Mark Walport, Director of the Wellcome Trust.
GSK European Seminar is by invitation only. Due to limited places, you can express your interest to attend by submitting your contact details to: seminar@isc-europe.com
A report of the seminar will be made available after the event. To receive a copy, please send an e-mail.GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. The company is has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn.
The meeting will be chaired by Giles Chichester MEP, Chairman of the European Parliament’s Industry Committee and speakers will include the European Commissioner for Research, Janez Potočnik, Tachi Yamada, the Chairman of R&D at GlaxoSmithKline and Mark Walport, Director of the Wellcome Trust.
GSK European Seminar is by invitation only. Due to limited places, you can express your interest to attend by submitting your contact details to: seminar@isc-europe.com
A report of the seminar will be made available after the event. To receive a copy, please send an e-mail.GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. The company is has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic.
GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn.